Clinical outcomes of ferroptosis-inducing agents in glioblastoma: A systematic review of clinical trials.
Younseo Choi, Yusuke S Hori, Koki Abe et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the clinical outcomes of ferroptosis-inducing agents in glioblastoma (GBM) patients. Fourteen studies were included, primarily focusing on sorafenib, with median progression-free survival ranging from 1.8 to 7.9 months and overall survival from 4.4 to 18.0 months. The findings highlight the variable efficacy and safety of these agents in GBM treatment.
Key findings
- Median progression-free survival for sorafenib ranged from 1.8 to 7.9 months.
- Overall survival for sorafenib trials varied from 4.4 to 18.0 months.
- Six-month progression-free survival rates varied significantly, from 0.0% to 86.7%.
- Grade ≥3 toxicities were reported in 32% to 65% of participants.
Why it matters
Understanding the efficacy and safety of ferroptosis-inducing agents in GBM is crucial for developing new treatment strategies, especially given the poor prognosis associated with this aggressive tumor type.
What to keep in mind
The predominance of early-phase, nonrandomized study designs limits definitive conclusions.